Pharma Launch Strategy: Why Most Drugs Fail in Market, Not in Development

Pharma launch strategy is the commercial plan that takes a drug from regulatory approval to revenue, covering market access, stakeholder engagement, channel mix, and positioning. Most pharmaceutical products that underperform commercially do so not because of clinical shortcomings, but because the commercial strategy was built too late, too narrowly, or too far removed from how prescribers and payers actually make decisions.

Getting this right requires more than a launch checklist. It requires a clear-eyed view of the market, honest positioning, and a commercial infrastructure that connects medical affairs, marketing, market access, and sales into a single coherent effort.

Pharma launch sits within a broader set of go-to-market disciplines, and many of the principles that apply to complex B2B or regulated industries translate directly. If you want a wider frame for commercial strategy, the Go-To-Market & Growth Strategy hub covers the full range of approaches across sectors and business models.

Why Do Pharma Launches Underperform?

I’ve worked across more than 30 industries over two decades, and regulated sectors have a particular pattern of failure that I find genuinely fascinating. The product is often excellent. The clinical data is strong. The unmet need is real. And yet the commercial trajectory flatlines within six months of launch.

The diagnosis is almost always the same: commercial strategy was treated as a downstream activity. The science team spent five to ten years building the asset. The commercial team got eighteen months to build the launch. That asymmetry creates a structural problem that no amount of sales force enthusiasm can fix.

Forrester has written about this tension in healthcare go-to-market, noting that device and diagnostics companies routinely underestimate the complexity of commercial readiness relative to product readiness. The same dynamic applies in pharmaceutical launches, where the commercial infrastructure, payer relationships, and stakeholder education all need to be built before the approval date, not after it.

There is also a positioning problem that runs through the industry. Too many pharmaceutical brands are positioned around mechanism of action rather than clinical outcome, and around clinical outcome rather than the lived experience of prescribers and patients. That is a messaging architecture built for medical conferences, not for the people who actually make prescribing decisions under time pressure in a clinic.

What Does Pre-Launch Commercial Strategy Actually Involve?

The phrase “pre-launch” in pharma is often used to describe the six months before approval. That is far too late. Genuine pre-launch commercial strategy starts at Phase II, sometimes earlier, and covers four interconnected workstreams.

The first is market shaping. Before you can position a drug, you need to understand how the market currently thinks about the condition it treats. What do prescribers believe about existing options? Where are the frustrations? What does “good enough” look like to a payer? This is qualitative intelligence work, and it takes time to do properly. The findings from this work should be feeding back into clinical development, not sitting in a commercial deck that nobody reads until month minus six.

The second is payer strategy. Reimbursement is not a post-approval problem. The health technology assessment process, the value dossier, the comparative effectiveness argument, all of this needs to be built in parallel with the clinical programme. I’ve seen launches where the drug had strong Phase III data but the value dossier was assembled in a hurry and the reimbursement outcome was worse than it needed to be. That is a commercial failure with a clinical disguise.

The third is KOL and medical affairs strategy. Key opinion leader engagement in pharma has a reputation for being relationship-driven to the point of being transactional. The better approach is to identify the scientific narrative that the clinical data supports, and then find the voices in the medical community who genuinely believe it and can articulate it credibly. That is a different exercise from building a speaker bureau.

The fourth is commercial infrastructure. Sales force sizing, territory design, digital channel architecture, medical information systems, patient support programmes. These are operational questions, but they sit inside the strategy. Getting the sizing wrong in either direction has direct revenue consequences. Before any of this is finalised, a thorough digital marketing due diligence exercise is worth running, particularly to assess the competitive digital landscape, channel readiness, and any gaps in owned media that need to be addressed before launch.

How Should You Build the Launch Positioning?

Positioning in pharma is harder than in most categories because you are operating inside a regulated messaging framework, the audience is highly educated and sceptical, and the competitive set is often well-established. The temptation is to default to data-led messaging: efficacy percentages, response rates, tolerability profiles. That is not positioning. That is a label.

Real positioning answers a different question: why should a prescriber change their behaviour? Behaviour change is the commercial objective, and it requires understanding what is currently driving that behaviour. Is it habit? Familiarity with a competitor’s side effect profile? Uncertainty about patient selection? Each of these requires a different message and a different channel.

I think about this through the lens of what I saw when working on campaigns across multiple regulated categories. The brief that said “tell them it works” was always the brief that produced the weakest commercial result. The brief that said “tell them why their current approach is leaving something on the table” was the one that created genuine prescriber engagement. The science has to be there, but the science alone does not move behaviour.

BCG has made a similar observation in their commercial transformation work, noting that go-to-market strategy in complex categories requires a genuine commercial thesis, not just a product narrative. In pharma, that means being explicit about the clinical context in which your drug is the right choice, and the clinical context in which it is not. That kind of intellectual honesty builds prescriber trust faster than any promotional campaign.

For teams building their positioning architecture, running a structured website and digital presence audit early in the process can surface gaps between what the brand claims and what the digital footprint actually communicates. In pharma, where HCPs and payers increasingly conduct independent research before any sales conversation, that gap matters.

What Role Does Digital Play in a Pharma Launch?

Digital in pharma is chronically under-utilised, and the reason is almost always compliance anxiety rather than strategic logic. Medical-legal-regulatory review processes are slow, and digital channels move fast, so the default position in many organisations is to keep digital minimal, keep it safe, and keep it out of the critical path. The result is a launch that is heavily dependent on field force activity and traditional media at exactly the moment when prescriber behaviour is shifting toward digital information sources.

The smarter approach is to build digital into the MLR process from the start, not to treat it as a separate stream. That means having compliant content frameworks in place before launch, not scrambling to get digital assets approved in the final weeks. It means having an HCP portal strategy, a patient support digital infrastructure, and a search presence that reflects the clinical questions prescribers are actually asking.

Endemic advertising, meaning advertising placed within the professional digital environments where HCPs actually spend their time, is one of the most consistently undervalued channels in pharma marketing. Journals, clinical decision tools, medical education platforms, these are the environments where prescribers are already in a clinical mindset. Endemic advertising in these contexts tends to produce better quality engagement than broad programmatic approaches, and it is easier to defend from a compliance perspective because the context is inherently professional.

I ran a paid search campaign at lastminute.com that generated six figures of revenue in under 24 hours from a relatively simple setup. That experience taught me something that I have applied in every sector since: the channel works when the intent signal is right and the message matches the moment. In pharma, search intent from HCPs researching a new drug is one of the strongest intent signals available. Most brands are not capturing it effectively.

How Do You Manage the Multi-Stakeholder Complexity of a Pharma Launch?

Pharma launches involve more stakeholders than almost any other commercial category. Prescribers, patients, payers, pharmacists, hospital formulary committees, patient advocacy groups, medical affairs teams, regulatory bodies. Each has different information needs, different decision criteria, and different timelines. The commercial plan has to hold all of this together without becoming a document that tries to be everything to everyone and ends up being nothing to anyone.

The way I have seen this done well is through a clear stakeholder prioritisation framework that is explicit about sequencing. Not all stakeholders need to be activated at the same time. In most launches, payer engagement should precede prescriber promotion, because without reimbursement, prescriber demand creates frustration rather than revenue. Medical affairs engagement with KOLs should precede commercial promotion, because the scientific narrative needs to be established before the promotional narrative can land credibly.

This sequencing logic also applies to the sales function. There is a version of pharma launch strategy that deploys the full sales force on day one of approval and burns through prescriber goodwill with premature promotional calls. The better approach is to use the pre-approval period to build genuine scientific relationships, so that when commercial promotion begins, it is reinforcing a conversation that has already started rather than starting a new one from scratch.

The multi-stakeholder complexity in pharma has some structural parallels with B2B financial services, where regulatory constraints, long decision cycles, and multiple buyer personas create similar challenges. The B2B financial services marketing frameworks for managing complex stakeholder environments are worth reviewing, particularly around how to sequence content and channel activity across a long sales cycle.

For organisations that are thinking about how their commercial and marketing functions are structured relative to launch complexity, the corporate and business unit marketing framework developed for B2B tech companies offers a useful structural model. The question of where brand strategy sits relative to product or therapy area marketing, and how those functions coordinate around a launch, is one that many pharma organisations have not resolved cleanly.

What Does the First 12 Months Actually Determine?

There is a commercial reality in pharma that does not get discussed enough in launch planning conversations: the first 12 months set the commercial ceiling for most products. Drugs that launch slowly rarely recover their trajectory. The reasons are structural. Prescribers who try a new drug early and have a positive experience become advocates. Those who are not reached early default to established habits. Payers who see weak uptake in the first year become harder to negotiate with in year two. The launch window is real, and it closes.

This is why the pre-launch investment question matters so much. Organisations that treat launch as a cost to be minimised until approval is confirmed consistently underperform against those that treat pre-launch as the most leveraged investment in the commercial lifecycle of the asset. The asymmetry of return is significant: spending more earlier, when the market is forming its initial view of the drug, produces better outcomes than spending the same amount later trying to correct a weak launch trajectory.

I have seen this pattern play out in non-pharma categories too. When I joined an agency in a turnaround situation and we were building new client relationships, the temptation was always to be conservative on investment until we had proof of performance. The problem was that conservative early investment produced conservative early results, which made the proof harder to generate. The same logic applies in pharma. You cannot validate a launch strategy on a minimal budget and then scale what works, because the launch window does not wait for your validation cycle.

For teams that are thinking about how to generate early commercial traction, particularly in markets where the sales cycle is long and relationship-dependent, pay-per-appointment lead generation models offer an interesting structural comparison. The principle of focusing commercial investment on converting qualified engagement rather than generating broad awareness has direct application in pharma, where the target prescriber universe is often relatively small and well-defined.

What Are the Most Common Strategic Mistakes in Pharma Launches?

After working across a range of regulated and complex commercial categories, the mistakes I see most consistently in pharma launch strategy fall into four categories.

The first is late commercial planning. The clinical team runs the asset for years, and the commercial team is expected to be ready in months. This is a resource allocation problem masquerading as a planning problem. The fix is structural: commercial leadership needs a seat at the table during Phase II, not Phase III.

The second is positioning by committee. When the medical affairs team, the brand team, the market access team, and the regulatory team all have input into the core message, the result is usually a message that offends nobody and moves nobody. Strong launch positioning requires a clear owner and a willingness to make choices that some internal stakeholders will not love.

The third is over-reliance on the sales force. Field force activity is still important in pharma, but the idea that a large enough sales force can compensate for weak positioning, poor market access, or an underdeveloped digital presence is a legacy assumption. Prescribers have less time for sales calls than they did ten years ago, and the quality of the interaction matters more than the frequency.

The fourth is treating patient strategy as secondary. In many therapy areas, patient activation, whether through advocacy groups, patient support programmes, or direct-to-patient communication, is a meaningful driver of prescribing behaviour. Patients who ask their physician about a specific treatment by name create a different kind of commercial dynamic than patients who passively receive whatever is prescribed. Building the patient strategy in parallel with the HCP strategy, rather than as an afterthought, is one of the clearest differentiators between strong and weak launches.

The commercial transformation literature from BCG reinforces this point about integration. Their work on scaling commercial agility highlights that organisations which break down functional silos in their go-to-market execution consistently outperform those that run parallel workstreams that never fully converge. In pharma, that convergence problem is acute, and solving it is a strategic priority, not an operational one.

There is also a measurement problem worth naming. Pharma organisations often have sophisticated data on prescription volumes and market share, but relatively weak data on the commercial activities that drive those outcomes. Attribution in pharma is genuinely difficult, but the response to that difficulty should not be to measure only what is easy. Go-to-market execution is getting harder across most sectors, and pharma is not exempt from that trend. The organisations that build better commercial intelligence infrastructure during the launch period are the ones that make better decisions in years two and three.

I spent time early in my career in a brainstorm that I was not supposed to be leading. The founder handed me the whiteboard pen and left for a client meeting. My instinct was to be cautious, to facilitate rather than direct. What I learned from that experience was that the room needed someone to make a call, not someone to manage the process. Launch strategy has the same dynamic. The organisations that launch well are the ones where someone is willing to make a clear call on positioning, sequencing, and investment, and then hold the line when the internal pressure to hedge starts building.

If you are working through a broader commercial strategy challenge beyond the launch itself, the Go-To-Market & Growth Strategy hub covers the frameworks and approaches that apply across the full commercial lifecycle, from initial market entry through to category leadership.

About the Author

Keith Lacy is a marketing strategist and former agency CEO with 20+ years of experience across agency leadership, performance marketing, and commercial strategy. He writes The Marketing Juice to cut through the noise and share what works.

Frequently Asked Questions